01 September 2005
Systemic Lupus Erythematosus (SLE) in Italy: an Italian prevalence study basedon a two-step strategy in an area of Florence (Scandicci-Le Signe).
Maurizio Benucci, Angela Del Rosso, Francesca Li Gobbi, Mariangela Manfredi, Marco Matucci Cerinic, Carlo SalvaraniMed Sci Monit 2005; 11(9): CR420-425 :: ID: 428449
Abstract
Background: The goal was to ascertain the prevalence of SLE in the populationover18 years of age in the Scandicci-Le Signe area of Florence, Italy, based on the records of generalpractitioners (GPs). Material/Methods: Twenty GPs screened 32,521 patients by administering the LupusScreening Questionnaire (LQS) and found 30 patients with suspected or definite diagnosis of SLE. To confirmthe diagnoses the patients were referred to a rheumatologist who conducted routine examinations and assessedantinuclear antibodies and SLE activity (ECLAM score). Results: Total population >18 years of age inthe three municipalities was 71,204 persons, with 42,474 in Scandicci, 15,368 in Lastra a Signa, and13,362 in Signa. In 23/30 patients diagnosed with SLE the diagnosis was confirmed. Eleven of the 23 SLEpatients were from Scandicci and 6 each from Lastra a Signa and Signa. An overall estimated prevalenceof SLE of 71/100,000 (1/1408; 95% CI=49, 92) was found in the total population of the three municipalities.Scandicci (95% CI=42, 121) had a rate of 81/100.000, while Lastra a Signa (95% CI=32, 92) and Signa (95%CI=36, 94) had estimated rates of 62/100,000 and 65/100,000, respectively. Medium ECLAM score was 4.68+/-1.81SD. Conclusions: This is the first epidemiological study on SLE prevalence in Italy. The prevalence andpoint prevalence are similar to other European studies. The LQS was also confirmed as an easy and reliabletool to assess SLE diagnosis in the Italian population.
Keywords: Family Practice, Italy - epidemiology, Lupus Erythematosus, Systemic - epidemiology, Mass Screening, Questionnaires, Rheumatology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952